Skip to content
Contact us
CNS Splash
CNS Market Research for Neurology & Psychiatry
 

CNS Market Research for Neurology, Psychiatry & Rare Neurological Conditions

In CNS, brands that win are not the loudest, they are the most clinically credible. With 120+ drugs competing for neurologist attention, no single brand commanding more than 5% of unaided recall, and pipeline drugs forming HCP perception before approval, ZoomRx helps pharma teams build and protect the mindshare that drives prescribing.
Talk to an CNS Research Specialist

Why CNS Is One of the Hardest Markets to Navigate With Generic Research

Your therapy is invisible in a crowded market

 When no single drug holds more than 5% of neurologist recall, being "good enough" is not enough. A therapy without a category ownership strategy disappears into the noise, regardless of how strong the clinical data is.

Neurologists don’t think in brands, they think in mechanisms and indications

Positioning a CNS drug as "a neurology treatment" means nothing to a neurologist. They organize their prescribing around drug class and indication. If you’re not the monoclonal antibody for MS or the CGRP inhibitor for migraine, you’re not differentiated.

Psychiatric pipeline brands must earn excitement before approval

HCP perception of pipeline drugs forms months before registration data is complete. Psilocybin, IV Ketamine, and NRX-101 achieved significant psychiatrist mindshare before regulatory approval. Brands that wait until launch to build awareness start behind.

Manufacturer reputation shapes prescribing before your sales team walks in the door

In CNS, two-thirds of HCPs are reluctant to prescribe from a manufacturer with a poor reputation. A brand’s commercial performance in neurology is inseparable from how the company is perceived, not just how the product performs.

Research That Drives Your Next Decision, Not Just Your Next Report

Every ZoomRx CNS program is built around the commercial question your brand team is actually trying to answer, from pre-launch category positioning to in-market mindshare defense.

Brand Tracking (ATU)

Continuous HCP tracking that goes beyond KPIs to actions, surfacing the shifts in neurologist and psychiatrist awareness, perception, and prescribing intent that tell your team what to do next, not just what happened.

Explore
Promotional Effectiveness Tracking (PET)
Fully custom research built around your CNS brand, your HCP audience, and your indication, not a syndicated tracker applied to your data. Tells you what your specific prescribers respond to, not what the category average shows.

 

explore
Pre-Launch & Launch Intelligence
Research from Phase II through launch that answers what your team cannot afford to get wrong: which HCPs to prioritize, how your mechanism fits the clinical framework neurologists already use, and what perception gaps to close before launch day.

 

explore
HCP-Patient Conversations

HIPAA-compliant research capturing authentic clinical dialogue in neurology and psychiatry consultations, the treatment decisions, adherence conversations, and patient trust dynamics that are invisible in standard HCP surveys.

Explore
Ferma Congress Intelligence
Real-time coverage of AAN, ECTRIMS, APA, and 250+ global conferences. Ferma analyzed all 4,250 AAN 2023 abstracts alongside social media to identify the sessions that actually moved neurologists, your team gets the signal, not the noise.

 

explore
Patient Chart Audits (PCA)
Voice-first AI capturing how neurologists and psychiatrists navigate treatment sequencing, side effect conversations, and the patient factors that determine whether a prescribed therapy is actually used.

 

explore
INDICATIONS — NEUROLOGY
Multiple Sclerosis Epilepsy / Seizure Disorders Migraine Parkinson's Disease Alzheimer's Disease ALS Rare Neurological Conditions
INDICATIONS — PSYCHIATRY
Depression Schizophrenia Bipolar Disorder Anxiety PTSD ADHD Treatment-Resistant Depression

What Makes ZoomRx Different in CNS Market Research

CNS-Icon 1
Research built around how neurologists and psychiatrists actually think - by mechanism and indication, not brand
 
ZoomRx structures CNS research around drug class and indication, the framework both neurologists and psychiatrists use so your therapy’s position is measured against the category it needs to own, not just its named competitors.
CNS-Icon 2
Custom research, not a syndicated panel applied to your CNS brand
 
Every ZoomRx CNS program is designed around your specific HCPs, your indication, and your competitive context, neurologists, psychiatrists, or both, depending on where your brand competes.
CNS-Icon 3
Manufacturer reputation tracking that surfaces perception gaps before they become commercial problems
 
ZoomRx tracks how neurologists and psychiatrists perceive competing manufacturers across portfolio, access, and promotions on a quarterly basis — so your team sees reputation dynamics before they show up in prescribing data.
CNS-Icon 4
Congress intelligence that turns AAN and ECTRIMS abstracts into commercial decisions
 
Ferma analyzed all 4,250 AAN 2023 abstracts alongside social media and news to identify the sessions that actually changed neurologist thinking, not a summary of what was presented, but what moved the field.
CNS-Icon 5
One team holds the full picture from prelaunch through in-market
 
Pre-launch intelligence, brand tracking, promotional effectiveness, and patient research in one connected workflow, so context is never lost between vendors and no insight has to be rebuilt mid-campaign.

Explore Other Therapeutic Areas

ZoomRx delivers pharma market research across multiple therapeutic areas. Explore our research and capabilities by TA.
Oncology
From HCP brand tracking and promotional effectiveness to manufacturer perception studies and congress intelligence across 40+ indications.

 

explore
Metabolic

GLP-1s, diabetes, obesity — the fastest-growing TA in pharma. ZoomRx tracks brand dynamics, HCP adoption, and competitive intelligence across metabolic indications. 

Explore

CNS Intelligence Published by ZoomRx

Primary research conducted with practicing oncologists and hem-oncologists — not secondary data compilation.
neuro-brand-race
100+ Neuro Brands Race for Neurologist Mindshare
read more
ASCO conference
What Drives Psychiatrists’ Awareness and Excitement
read more
FiercePharmaArticle
Enhertu, Keytruda Lead Oncology HCP Marketing — Fierce Pharma
read more

CTA

Talk to a CNS Research Specialist

Tell us about your brand and research challenge. We’ll connect you with a ZoomRx CNS specialist who has worked across your indication, your competitive set, and your launch stage.

Get in touch

Frequently Asked Questions

How does ZoomRx research cover both neurology and psychiatry?

ZoomRx conducts separate primary research for neurology and psychiatry, reflecting distinct HCP audiences and prescribing dynamics. Neurology work covers MS, epilepsy, migraine, Parkinson’s, Alzheimer’s, ALS, and rare neurological conditions. Psychiatry research covers depression, schizophrenia, bipolar disorder, treatment-resistant depression, and pipeline candidates across novel mechanisms.

Why does manufacturer reputation matter in CNS market research?

ZoomRx tracks HCP perception of competing manufacturers across neurology and psychiatry on a quarterly basis. In CNS more than other TAs, manufacturer reputation directly shapes prescribing — two-thirds of HCPs are reluctant to prescribe from manufacturers with poor reputations. Biogen’s neurology leadership is built on portfolio reputation as much as individual product performance.

How do you choose a CNS market research partner?

Look for a team that understands how neurologists think by drug class and indication, not brand - tracks manufacturer reputation alongside product performance, and runs separate panels for neurology and psychiatry. ZoomRx is built for exactly this, with primary mindshare research across 120+ competing neurology drugs and quarterly HCP perception tracking across both specialties.